A Study to Test the Safety and Tolerability of Staccato Alprazolam in Study Participants 12 Years of Age and Older With Stereotypical Prolonged Seizures
Open the official record
This page only displays public information reproduced from the official ClinicalTrials.gov record NCT05076617. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Official title
An Open-Label, Multicenter, Outpatient Extension Study to Evaluate the Safety and Tolerability of Staccato Alprazolam in Study Participants 12 Years of Age and Older With Stereotypical Prolonged Seizures
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of the study is to evaluate the long-term safety and tolerability of Staccato alprazolam.
Study identification
- NCT ID
- NCT05076617
- Recruitment status
- Enrolling by invitation
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 300 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 12 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 3, 2022 (Actual)
- Primary completion
- Nov 30, 2028 (Estimated)
- Completion
- Nov 30, 2028 (Estimated)
- Last update posted
- Sep 25, 2026
2022 – 2028
United States locations
- U.S. sites
- 48
- U.S. states
- 21
- U.S. cities
- 39
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Ep0165 50506 | Phoenix | Arizona | 85004 | — |
| Ep0165 50720 | Scottsdale | Arizona | 85253 | — |
| Ep0165 50494 | Little Rock | Arkansas | 72205 | — |
| Ep0165 50118 | Downey | California | 90242 | — |
| Ep0165 50416 | La Jolla | California | 92037 | — |
| Ep0165 50702 | Long Beach | California | 90806 | — |
| Ep0165 50722 | Poway | California | 92064 | — |
| Ep0165 50716 | Sacramento | California | 95817 | — |
| Ep0165 50088 | Washington D.C. | District of Columbia | 20037 | — |
| Ep0165 50515 | Gulf Breeze | Florida | 32561 | — |
| Ep0165 50508 | Jacksonville | Florida | 32209-6533 | — |
| Ep0165 50342 | Jacksonville | Florida | 32224 | — |
| Ep0165 50199 | Miami | Florida | 33136 | — |
| Ep0165 50676 | Miami | Florida | 33176 | — |
| Ep0165 50509 | Orlando | Florida | 32806 | — |
| Ep0165 50703 | Rockledge | Florida | 32955 | — |
| Ep0165 50308 | Tampa | Florida | 33606 | — |
| Ep0165 50323 | Honolulu | Hawaii | 96817 | — |
| Ep0165 50512 | Boise | Idaho | 83702 | — |
| Ep0165 50493 | Chicago | Illinois | 60611 | — |
| Ep0165 50504 | Fort Wayne | Indiana | 46845 | — |
| Ep0165 50517 | New Orleans | Louisiana | 70122 | — |
| Ep0165 50615 | Boston | Massachusetts | 02118 | — |
| Ep0165 50047 | Boston | Massachusetts | 02215 | — |
| Ep0165 50507 | St Louis | Missouri | 63110 | — |
| Ep0165 50299 | New Brunswick | New Jersey | 08901 | — |
| Ep0165 50497 | Amherst | New York | 14226 | — |
| Ep0165 50625 | New Hyde Park | New York | 11042 | — |
| Ep0165 50298 | New York | New York | 10016 | — |
| Ep0165 50490 | New York | New York | 10029 | — |
| Ep0165 50518 | New York | New York | 10075 | — |
| Ep0165 50034 | Rochester | New York | 14642 | — |
| Ep0165 50514 | Charlotte | North Carolina | 28204 | — |
| Ep0165 50715 | Durham | North Carolina | 27705 | — |
| Ep0165 50701 | Portland | Oregon | 97239 | — |
| Ep0165 50096 | Philadelphia | Pennsylvania | 19104 | — |
| Ep0165 50364 | Philadelphia | Pennsylvania | 19107 | — |
| Ep0165 50089 | Philadelphia | Pennsylvania | 19140 | — |
| Ep0165 50511 | Pittsburgh | Pennsylvania | 15212 | — |
| Ep0165 50491 | Pittsburgh | Pennsylvania | 15213 | — |
| Ep0165 50700 | Chattanooga | Tennessee | 37403 | — |
| Ep0165 50513 | Memphis | Tennessee | 38103-2800 | — |
| Ep0165 50103 | Nashville | Tennessee | 37232 | — |
| Ep0165 50731 | Austin | Texas | 78749 | — |
| Ep0165 50714 | Houston | Texas | 77030 | — |
| Ep0165 50525 | Houston | Texas | 77459 | — |
| Ep0165 50473 | Salt Lake City | Utah | 84132 | — |
| Ep0165 50726 | Winchester | Virginia | 22601 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 88 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05076617, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 25, 2026 · Synced Nov 15, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.